Study Finds No Clear Link Between Prenatal Sedative-Hypnotic Use and ADHD or ASD in Children
Research Overview
A recent nationwide cohort study from Taiwan investigated whether prenatal exposure to sedative-hypnotic medications, commonly prescribed for anxiety and insomnia during pregnancy, is associated with an increased risk of attention-deficit/hyperactivity disorder (ADHD) or autism spectrum disorder (ASD) in offspring. The study focused on benzodiazepines and Z-hypnotics, two classes of sedative-hypnotics frequently used during pregnancy.
Study Design and Population
Researchers analyzed data from Taiwan’s National Health Insurance and Birth Registry spanning 2009 to 2016. To reduce confounding factors related to the underlying maternal conditions, the study included only live-born children whose mothers had documented diagnoses of insomnia, depression, or anxiety. This approach aimed to better isolate the effects of medication exposure from the effects of maternal psychiatric illness.
The study matched 25,159 children exposed prenatally to sedative-hypnotics with 50,318 unexposed children, pairing them by sex and birth date within a six-month range. The researchers then used Cox proportional hazards models to estimate the risk of ADHD and ASD, adjusting for maternal health and sociodemographic variables.
Key Findings
Initial crude incidence rates showed slightly higher rates of ADHD and ASD among exposed children compared to unexposed peers: 6.98 versus 6.09 cases of ADHD per 10,000 person-months, and 1.34 versus 1.15 cases of ASD per 10,000 person-months, respectively.
However, after adjusting for maternal psychiatric severity and familial factors, the associations between prenatal sedative-hypnotic exposure and neurodevelopmental disorders were no longer statistically significant. The adjusted hazard ratios were 1.08 (95% confidence interval [CI]: 0.99–1.18) for ADHD and 1.08 (95% CI: 0.88–1.32) for ASD, indicating no clear increased risk linked to medication use.
Implications for Families and Healthcare Providers
These findings suggest that previously reported associations between prenatal sedative-hypnotic use and neurodevelopmental disorders in children may be influenced more by the underlying maternal psychiatric conditions than by the medications themselves. For families and clinicians, this may provide some reassurance regarding the neurodevelopmental safety of these medications when prescribed during pregnancy, though careful consideration of risks and benefits remains essential.
Study Limitations and Cautions
As with all observational research, residual confounding cannot be entirely excluded. The study design, while rigorous, cannot definitively establish causality. The authors recommend further research employing methods that more precisely account for timing of medication use, initiation, and familial factors to clarify these relationships.
For those seeking more detailed information, the full study is available at PubMed.
Download the images in this article
